Data from Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition

MLA

Mitchell P. Levesque, et al. Data from Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition. Mar. 2023. EBSCOhost, https://doi.org/10.1158/1078-0432.c.6529838.

APA

Mitchell P. Levesque, Matthias Guckenberger, Reinhard Dummer, Martin W. Huellner, Ken Kudura, Robert Förster, Stephanie Tanadini-Lang, Diem Vuong, Marta Bogowicz, Matea Pavic, Sabrina A. Hogan, Hubert S. Gabryś, & Lucas Basler. (2023). Data from Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition. https://doi.org/10.1158/1078-0432.c.6529838

Chicago

Mitchell P. Levesque, Matthias Guckenberger, Reinhard Dummer, Martin W. Huellner, Ken Kudura, Robert Förster, Stephanie Tanadini-Lang, et al. 2023. “Data from Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition,” March. doi:10.1158/1078-0432.c.6529838.